Thymosin Alpha-1 5mg
Thymosin Alpha-1 is a 28-amino-acid peptide studied for T-cell maturation, dendritic function, and immune system modulation.
Mechanism
Thymosin Alpha-1 signals through Toll-like receptors such as TLR-2 and TLR-9 to enhance T-cell maturation, upregulate MHC Class I expression, and balance critical cytokine cascades.
Dosing
Standard research administration protocols document 1.6 mg (64 units on a U-100 syringe) injected subcutaneously twice weekly.
Reconstitution
Reconstituting a 5 mg vial with 2.0 mL of bacteriostatic water produces a working concentration of 2.5 mg/mL (2,500 mcg/mL).
Storage
Store the lyophilized peptide refrigerated at 2–8 °C or frozen at -20 °C, and maintain reconstituted solutions protected from light at 2–8 °C for up to 7 days.
Mix & measure Thymosin Alpha-1 5mg
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure Thymosin Alpha-1 5mg
Vial strength → BAC water → target dose
Common vial sizes
Label claim
Total doses in vial: 3.1
U-100 syringe: 100 units = 1 mL
Need supplies for this protocol?
Research-grade peptides, fast shipping, competitive pricing
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Track my protocol
Log each dose, build a streak, and watch your progress through this protocol's schedule.
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| Standard (all weeks) | 1.6 mg (twice weekly) | 64 units (0.64 mL) |
| Weekly total | 3.2 mg / week | 128 units (1.28 mL) |
Reconstitution Steps
- 1
Draw 2.0 mL of bacteriostatic water using a sterile syringe.
- 2
Gently inject the liquid down the inner glass wall of the 5 mg peptide vial to minimize agitation and foaming.
- 3
Carefully swirl or roll the vial between your palms until the powder is fully dissolved; avoid vigorous shaking.
- 4
Record the date and resulting concentration (2.5 mg/mL) on the vial label.
- 5
Place in cold storage at 2–8 °C (35.6–46.4 °F) shielded from light exposure.
Supplies Needed
Peptide Vial
Lyophilized Thymosin Alpha-1 (5 mg)
Insulin Syringes (U-100)
1 mL U-100 sterile syringes for measuring 64-unit doses
Bacteriostatic Water
2.0 mL used to dilute each 5 mg vial
Alcohol Swabs
Antiseptic preparation of vial tops and injection areas
Why researchers study it
Immune modulation and T-cell maturation
Chronic viral infection models (HBV/HCV)
Sepsis and critical illness immune support
Investigational vaccine adjuvant response
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
Thymosin Alpha-1 (thymalfasin) is an endogenous 28-amino-acid peptide originally isolated from thymic tissue. Within cellular biology models, it is widely investigated for its capacity to steer immune competency without triggering excessive systemic inflammatory responses. In laboratory and experimental models, researchers evaluate Thymosin Alpha-1 for its regulatory effects on innate and adaptive pathways. It acts primarily by stimulating early-stage thymocyte differentiation into mature helper and cytotoxic T-cell populations, alongside enhancing major histocompatibility complex (MHC) presentation and dendritic cell activation. While clinically approved in over 30 countries under proprietary trade names for conditions such as chronic viral hepatitis and immune deficiency states, research-grade Thymosin Alpha-1 remains restricted strictly to laboratory inquiry in jurisdictions such as the United States.
References
- 1.Dominari et al., World Journal of Virology, 2020 — Comprehensive review of Thymosin Alpha-1 mechanisms, dosing (0.8–6.4 mg SC), and clinical applications
- 2.Tao et al., Molecules, 2023 — Thymosin Alpha-1 in viral diseases: mechanisms and therapeutic applications in HBV, HCV, and HIV
- 3.Soeroto et al., Inflammopharmacology, 2023 — Meta-analysis of Tα1 in COVID-19; significant mortality reduction in moderate-to-critical patients
- 4.Expert Opinion on Biological Therapy, 2004 — Thymalfasin (Zadaxin) clinical overview: 1.6 mg SC twice weekly for hepatitis B treatment
- 5.Annals of the New York Academy of Sciences, 2007 — Thymosin Alpha-1: biological activities, clinical applications, and pharmacokinetics review
- 6.Clinical Immunology, 2007 — Mechanisms of thymosin alpha-1 immunomodulation: T-cell maturation and cytokine production
- 7.Journal of Hepatology, 2001 — Thymosin Alpha-1 as an immune adjuvant in chronic hepatitis B and C: clinical efficacy
- 8.Critical Care, 2013 — Thymosin Alpha-1 in severe sepsis and critical illness: immune restoration and outcomes
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.
Related protocols
View allBPC-157 + TB-500 10mg Blend
A 1:1 dual-peptide blend combining BPC-157 and TB-500 formulated to investigate complementary soft-tissue and wound-healing pathways.
View ProtocolPalmitoyl Tetrapeptide-7 200mg
A synthetic palmitoylated tetrapeptide studied in topical cosmetic formulations for modulating skin inflammation and matrix integrity.
View ProtocolTB-500 + BPC-157 5+5 mg
A dual-peptide research stack pairing TB-500 and BPC-157 in separate vials to investigate complementary soft-tissue and wound healing pathways.
View Protocol